Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant
plasma cell proliferation in the bone marrow (BM) and constitutes the second most common …

The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …

Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …

The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …

Several haematological malignancies, including multiple myeloma (MM) and acute myeloid
leukaemia (AML), have well-defined precursor states that precede the development of overt …

Plasmacytoid dendritic cells (pDCs), also called natural interferon (IFN)-producing cells,
represent a specialized cell type within the innate immune system. pDCs are specialized in …

Islands of CD123high cells have been commonly described in the bone marrow of patients
with chronic myelomonocytic leukemia (CMML). Using a multiparameter flow cytometry …

Following the discovery of plasmacytoid dendritic cells (pDCs) and of their extraordinary
ability to produce type I IFNs (IFN-I) in response to TLR7 and TLR9 stimulation, it is assumed …

Simple Summary CD123 is overexpressed in multiple hematologic malignancies. Advances
in CD123-targeted therapies over the past decade have positioned this molecule as an …

Plasmacytoid pre-dendritic cells (pDC) are a specialized DC population with a great
potential to produce large amounts of type I interferon (IFN). pDC are involved in the …